


ProBio

Biologics Discovery Service

From Target to Preclinical Candidates



Contents

01.About ProBio Biologics Discovery Center	01
02.Antibody Lead Generation Service	06
<i>ProSpeed™</i> Single B Cell Antibody Discovery Service	07
<i>Powerdoma™</i> Hybridoma Antibody Discovery Service	09
Human Naïve Library Antibody Discovery Service	11
Single Domain Antibody Discovery Service	12
03.Antibody Lead Optimization Service	14
Antibody Humanization Service	15
Antibody Affinity Maturation Service	16
Fc Engineering Service	17
Antibody Developability Optimization Service	17
04.Biologics Pharmacology Service	18
In Vitro Bioassay Service	19
In Vivo Pharmacology Service	21
05.Preliminary Developability Assessment Service	23



01

**About ProBio
Biologics Discovery Center**

About ProBio


ProBio, a subsidiary of GenScript Biotech Corporation, is a global player dedicated to providing premium end-to-end service from discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers. ProBio has established companies in the United States, the Netherlands, South Korea, and China (Hong Kong, Shanghai, and Nanjing) and other regions to serve global customers, and has helped customers in the United States, Europe, Asia Pacific and other regions obtain more than 70 IND approvals since October 2017.

Biologics Discovery Center

ProBio Biologics Discovery Center leverages 20-year experience in biologics discovery to offer customers end-to-end services from target to preclinical candidates (PCC). **We are dedicated to accelerating your biologics discovery process of getting potential PCCs with functionality and developability.**

Our Core Competences

We are a reputable biologics discovery solution provider offering integrated services with *speed, quality, and cost-efficiency*



Excellence Proven by Impressive Track Record

20 years

EXPERTISE IN BIOLOGICS

20

2000+

2000+

PROJECT EXPERIENCE

2+

PROJECTS MARKETED

2+

1000+

1000+

GLOBAL PARTNERS

16

THERAPEUTIC ANTIBODY
LICENSING DEALS

16

17+

17+


PROJECTS IN THE
CLINICAL PHASE

*By Dec. 2024

Highly Integrated Discovery Platforms for Faster Advancement to the Clinical Stage!

Lead Generation

- 6 Technology Platforms to Get Leads with Good Qualities



Lead Optimization

- Antibody Sequence Optimization
- Developability and Functionality Optimization



Developability Assessment

- Selection of Final Candidate before CMC



In Vitro Bioassay

- Comprehensive Cell-based Assays to Evaluate the In Vitro Function

In Vivo Pharmacology

- In Vivo Pharmacology Platforms to Assess PK/PD/Potency In Animal Models

Bringing Together Various Technical Campaigns under One-roof

In Vivo Ab Lead Generation



Hybridoma



Single B cell screening



Immunized library



Fully human transgenic mice

In Vitro Ab Lead Generation



Fully human naïve library



Alpaca naïve library

Accelerating the Discovery of “Me-better” Antibody Candidates

Functionality Optimization

Antibody affinity maturation

10-fold affinity improvement guaranteed

Fc engineering

ADCC, CDC, ADCP enhancement, STR Fc silencing technology and half-life extension

Developability Optimizations

Antibody Humanization

Industry-leading timeline in **2.5 weeks**

Antibody Developability

Prediction, optimization, and assessment

Well-established Pharmacology Platforms in House

Assays & Animal Models

- Ready-to-use bioassays for **100+** popular targets
- **500+** proprietary assay cell lines
- Various efficacy models for different indications: **On-cology, metabolic and autoimmune disease**

Tailored Full-service Capability


- Customized assay cell lines
- Method development for various bioassays
- Method development for DMPK and bioanalysis (PK/TK, ADA, Biomarkers)

Tailored Discovery Strategies for Various Biologics Modalities, Ensuring the Success Rate!

Cell Therapy

1 approved drug

- Discovery of fully-validated antibody candidates with desirable affinity, epitope and sequence diversity by well-suited discovery strategy for CAR lead candidates
- All-inclusive CAR-T/NK bioassay services from vector construction & cell transduction to functional assay




Monoclonal Antibody

10+ projects in clinical trial

Expertise in Ab discovery for multi-pass membrane targets:


- mRNA and VLP immunization strategies to boost stronger immune response
- Powerdoma™ hybridoma technology to increase positive clone rate with shorter TAT
- Well-established bioassays and in vivo pharmacology platforms to functionally evaluate Ab candidates



Bispecific Antibody

2+ projects in clinical trial


- Customized bsAb formats based on the target, MOA, and customer's needs
- 4 types of bsAb bioassay platforms:
(cell-engager, dual-target blockade, dual immunomodulators, and cell surface protein bridging)
- An array of ready-to-use building blocks (mAbs and sdAbs) for fast and convenient construction & testing of bsAbs of interest



Antibody Drug Conjugate

2+ projects in clinical trial

- Identifying functional Abs with "precise targeting, efficient internalization" in the early screening stage
- Large payload-linker library: 150+ cytotoxins, 950+ linkers and 190+ conjugates
- Live-cell imaging-based internalization assay with speed, high-throughput and consistency



*By Jan. 2024


02

Antibody Lead Generation Service

<i>ProSpeed™</i> Single B Cell Antibody Discovery Service	07
<i>Powerdoma™</i> Hybridoma Antibody Discovery Service	09
Human Naïve Library Antibody Discovery Service	11
Single Domain Antibody Discovery Service	12

ProSpeed™ Single B Cell Antibody Discovery Service

Unparalleled Speed! Screening Completed in 1 Day
High-throughput, High-resolution Screening for Diverse Desirable Antibody



1 Month!
To Get Functional Antibody Sequence

A EXPEDITED TIMELINE

- Multiple sequential in-chip screening completed in 1 day
- 2 weeks from B cell exporting to final validated Ab sequences acquisition

B HIGH DIVERSITY

- Forward functional screening for the largest B cell pool possible, minimal diversity loss
- High throughput binder assays using ProSpeed™ expression, avoid missing high-quality leads!

Why Choose ProBio?

EXTENSIVE EXPERIENCE


- Introduction of the Beacon platform since 2019
- Delivery of over **150 projects**
- Extensive experience in various targets

A PERFECT COMBINATION WITH PROSPEED™ EXPRESSION AND BEACON® PLATFORM

- Higher throughput Ab expression and assay
- Breaking through the technical limitations on Beacon screening
- Cutting more than half of the cost and timeline in confirming functional binders

*By Dec. 2024

Case Study: DLL3 mAb Discovery by Beacon




Up to 4 sequential assays were included in the screening workflow

Assay Type	Positive Binders
Human DLL3	98
Cyno DLL3	127
Mouse DLL3	58
Human DLL3 cell	50

Exported Cross	Unique Sequence
61 out of 100	21 out of 23


Phylogenetic tree

Sequences discovered from Single B screening (green) are highly diverse and clustered to many different branches of the phylogenetic tree.




Various binding affinity to cell surface DLL3 and different binding epitopes

FACS Binding - CHO-K1/human DLL3(+)




Competition with BMK1 by FACS



BMK1:Rovalpituzumab; BMK2:Tarlatamab-DLL3-IgG1

Powerdoma™ Hybridoma Antibody Discovery Service

An Upgrade of Conventional Hybridoma Technology



3 Months
to Get Functional Ab Sequences

A STREAMLINED PROCESS

- Elimination of cumbersome two-month subcloning steps for greater efficiency
- Powerdoma™ timeline: 3-4 months
- Traditional timeline: 4-6 months

B FUNCTIONAL SCREENING FORWARD

- Use hybridoma supernatant for high-throughput cell-based functional assays (such as internalization assay), identify more high-potential leads at the earliest stage

Why Choose ProBio?

20 years of experience

880+ hybridoma-based Ab lead generation projects

17+ projects in the clinical stage

Impressive success rate in mAb lead generation


>95% for soluble & single transmembrane targets

>85% for multiple transmembrane targets

*By Dec. 2024


Case Study: Faster to Get More Positive Antibody Sequences with Powerdoma™ Platform

- Screening funnel



- Fast and efficient cell fusion and the fused hybridoma is monoclonal
- As fast as 1.5 month to get positive sequence
- More positive clones from Powerdoma™ platform

- Some binders showed higher affinity




Human Naïve Library Antibody Discovery Service

Large Library Size & Good Donor Diversity to Allow Discovery of High Affinity Leads

High-quality Human Naïve Library with Good Donor Diversity!


Donors from both sexes, various races & all blood types

Donor ethnicity distribution



White Black Asian

Donor blood type distribution



A A(-) AB AB(-) B B(-) O (-)


Library Features

Source	~1000 healthy donors
Material	Human PBMC
Library	Phage Fab library
Total size (cfu)	1.0x10 ¹¹ (in expansion)
Insertion rate	>95%
In-frame rate	>85%
Diversity rate	>95%
CDR3 diversity	Normal distribution
Tag	His & c-Myc
Affinity with SPR	1E-8~1E-10M
Typical TAT	~ 2 months


*By Jan. 2024

Case Study: PD-L1 mAb Discovery

Screening funnel



Higher binding and blocking profile than BMK



Key indicators of the best Ab lead

Criteria	Lead	BMK1-Avelumab
ELISA EC50 (nM)	0.2	0.7
FACS EC50 (nM)	0.13	0.51
Affinity by SPR (M)	3.05E-10	8.34E-10
Binding to mPDL1 EC50 (nM)	0.18	0.30
Binding to cynoPDL1 EC50 (nM)	0.68	0.88
Epitope binning	overlapping	/
PD1/PD-L1 blockade assay (EC50, nM)	0.17	1.41

Single Domain Antibody Discovery Service

Two sdAb Lead Generation Approaches to Increase Success Rate

sdAb Naïve Library

Faster timeline
Higher diversity

- 300 Alpaca donors;
- Library size: 2×10^{11}
- In frame rate/ORF rate:
>95%

1.5-2 months

sdAb Immunized Library

Higher affinity
Higher positive hit rate

- Easy access to Alpaca farm
- Using **only naïve Alpaca** for each project

3 -4 months

SPSSdAb™ Platform



Soluble supernatant based phage screening for sdAb discovery

- 2 antibody formats expressed during the phage display screening phase: phage expression & soluble expression

Advantages

- Inducible sdAb expression in supernatant
- Extremely high affinity of SASA tag (pmol for BSA) to allow high throughput affinity ranking by SPR
- Further elimination of false positive clones by SPR ranking


Why Choose ProBio?



*By Dec. 2024

Case Study: CD7 sdAb Discovery Using Immunized Library

- Screening funnel




Multiple humanized CD7 VHH leads were discovered showing higher affinity and more potent blockade of CD7 cell surface expression, comparing with the BMK Ab PA3-17-VHH6 (PersonGen).


Ligand	Analyte	Chi ² (RU ²)	ka (1/Ms)	kd (1/s)	KD (M)	Rmax (RU)
Lead 1-VHH3-Fc	CD7	1.05E-01	4.40E+05	5.19E-05	1.18E-10	76.1
Lead 2-VHH1-Fc	CD7	5.79E-02	2.43E+05	3.18E-05	1.31E-10	100.3
Lead 3-VHH1-Fc	CD7	4.87E-01	3.04E+05	3.04E-05	1.00E-10	77.3
PA3-17-VHH6 (BMK)	CD7	2.88E-01	9.79E+04	1.25E-04	1.28E-09	210

Potent target cell killing was mediated by CAR-T cells with a CAR composed of these VHH leads, confirming their functionality and good potential as CAR component.

Target :Jurkat/Luc killing assay



Target :CCRF-CEM/Luc killing assay



03


Antibody Lead Optimization Service

Antibody Humanization Service	15
Antibody Affinity Maturation Service	16
Fc Engineering Service	17
Antibody Developability Optimization Service	17

Antibody Humanization Service

As Fast as 2.5 Weeks to Get Your Antibody Humanized

2.5 weeks, get humanized antibodies with high expression levels, good thermal stability, and comparable affinity with the parental antibodies



Why Choose ProBio?

Extensive experience

20-year experience in antibody discovery
 Delivered over **600 projects**
 The most advanced project is **marketed**

*By 2024.12

Top-notch delivery


Delivery in as fast as 2.5 Weeks
 Guarantee **no loss of affinity**
 Humanization rate **>95%**
 Provide developability prediction reports including **PTM, aggregation and immunogenicity**

Case Study: Experienced in Various Ab Formats (mAb, scFv and sdAb)

Case Study 1: Mouse IgG Humanization

Affinity kinetic analysis

samples	Chi ² (RU ²)	ka (1/Ms)	kd(1/s)	KD (M)	Rmax (RU)
humanized antibody	5.03E-02	3.67E+05	6.90E-05	1.88E-10	70.5
parental antibody	2.11E-01	4.02E+05	5.56E-05	1.38E-10	73.6




Affinity is maximally retained by rational design

Case Study 2: VHH Humanization

Affinity kinetic analysis

Ligand	Analyte	ka (1/Ms)	kd (1/s)	KD (M)	Rmax (RU)	Chi ² (RU ²)
VHH WT	Ag	3.57E+04	2.52E-04	7.05E-09	127.1	0.682
VHH2	Ag	1.50E+04	2.75E-04	1.83E-08	148.9	0.315
VHH3	Ag	3.26E+04	2.46E-04	7.54E-09	136.8	0.694
VHH4	Ag	3.46E+04	2.42E-04	6.99E-09	117.4	0.57
VHH5	Ag	3.40E+04	2.19E-04	6.43E-09	172.3	0.99



Affinity is maximally retained by rational design


Antibody Affinity Maturation Service

Combination of Proprietary Precise Mutagenesis Library & High-throughput Screening Platform (FASEBA)

More comprehensive screening strategies, guarantee 10-fold improvement!



1 Precise Site-Saturation Mutagenesis Library, PML




Exhaustive mutagenesis possibilities

- Semiconductor-based oligo synthesis technology
- Precise site-saturation mutagenesis to ensure even distribution of 18 mutated amino acids at each residue
- No stop codons and unexpected codons

2 FASEBA High-throughput Screening Platform

F Fast
S Screening of
E Expression
B Biophysical-properties and
A Affinity



Quickly screen out molecules with the highest affinity, expression level and the best biophysical properties.

- Technology introduced from National Research Council Canada
- Affinity ranking by SPR was performed with prokaryotic expression supernatant, which greatly reduces the cost and cycle of recombinant expression, and ensure the success rate of screening.

Case Study: 1316-fold Affinity Improvement, from 10^{-7} to 10^{-10}

Ligand	Analyte	Chi ² (RU ²)	ka (1/Ms)	kd (1/s)	KD (M)	Rmax (RU)
WT	Target C	1.33E+00	3.79E+05	2.53E-01	6.66E-07	162.9
variant1	Target C	5.37E-02	3.77E+05	5.50E-04	1.46E-09	45.3
variant2	Target C	8.22E-02	5.87E+05	3.74E-04	6.38E-10	50.5
variant3	Target C	3.76E-02	4.92E+05	2.49E-04	5.06E-10	49.9

Fc Engineering Service

- Fc engineering service:
 - ✓ Fc silence
 - ✓ ADCC, CDC, ADCP enhancement
 - ✓ Half-life extension

- One-stop Fc engineering solution from sequence design to pharmacology study

Case Study 1: STR Silencing Technology

A cell-based reporter assay (Fig 6a) showed that the STR variant had no activity on all FcγRs compared to wild-type IgG1, LALA, and aglycosylated variants. A cytokine release assay with PBMCs isolated from healthy donors showed (Fig 6b) that STR exhibited no significant activity above buffer alone for all cytokine measured. **STR silencing technology truly abolishes the Fc domain effector function.**

* Data comes from mAbsolve




Fig. Cell-based assay for different Fc silence mutants

Case Study 2: ADCC and CDC Enhancement

The potency of ADCC and CDC against PA-1 target cells of two mutated Fc constructs was evaluated. As reported, the published Fc mutation sequences showed enhanced ADCC and CDC activities on PA-1 cells.





Fig. Cell-based assay for different Fc mutants

Antibody Developability Optimization Service

- One-stop developability solution from prediction to optimization
- PTM optimization: Guarantee no affinity loss
- Antibody aggregation optimization: guarantee at least 5-fold yield improvement

The developability prediction **allows optimization of PTM sites and hydrophobic regions** to obtain antibody candidates with better developability.




04

Biologics Pharmacology Service

In Vitro Bioassay Service	19
In Vivo Pharmacology Service	21

In Vitro Bioassay Service

A Versatile Platform for Functional Evaluation



6 Featured Functional Assay Platforms

Bioactivity of monoclonal Ab Fab domain

1. Functional assays

- Binding Assays
- Agonist activity
- Ligand blockade activity
- Neutralization Assays

2. Preclinical safety assessment

- Cytokine release syndrome assessment
- Species cross-reactivity assessment

3. Customized primary cell assays

- T/Treg, NK, macrophage, etc.

Bispecific Ab characterization

1. In trans cell bridging assay

- T cell engager
- NK cell engager
- Anti-TAA x immune checkpoint (stimulatory or inhibitory)

2. Dual target blockade/modulatory assay

- Immune cell activation
- Downstream signaling pathway analysis

3. In cis cell surface protein bridging assay

Cell line engineering

1. Target overexpression cells

2. Reporter gene cell and assay development

3. Customized bioactivity assays based on cell lines

4. Customized primary cell engineering

- T, NK, macrophage, etc.

Bioactivity of monoclonal Ab Fc domain

1. ADCC effect evaluation

- PBMC
- Reporter gene cell
- Primary NK cell/NK cell line

2. ADCP effect evaluation

- Primary macrophage cell
- Reporter gene cell

3. CDC effect evaluation

- Complement proteins
- Normal human pooled serum

4. Customized primary cell assays

- T/Treg, NK, macrophage, etc.

ADC lead characterization

1. Antibody internalization assay

- Live-cell imaging based Internalization
- pH-indicator-based internalization
- Toxin-conjugated mAb-based cytotoxicity assay
- Temperature shift-based internalization

2. Cytotoxicity assay

- Cell viability assay
- Cell apoptosis assay
- Cell cycle analysis assay

3. By-stander effect

- Medium transfer or co-culture assay

Other functional analysis platforms

1. CGT functional characterization

- CAR-T, CAR-NK
- AAV

2. Virus packaging and testing & VLP display

3. GPCR drug screening and evaluation

- Calcium flux; cAMP; beta-arrestin

4. Cell apoptosis/cycle analysis/growth


- Annexin-V/PI staining
- Caspase-3 activity

Case Study


ADC Lead Characterization: 8 Assay Formats Available for ADC Evaluation

Upgraded strategy: real-time live cell imaging-based internalization and bystander effect assay

Time course study




Dose response study



The **Incucyte® live-cell analysis system** enables direct detection of antibody internalization in a 96-well plate. Cells were treated with either Incucyte® FabFluor labeled anti-ROR1 antibody (UC-961) or hIgG1 isotype control. Dose response study showed a rapid increase in red object area in CHO-K1/ROR1 cells treated with anti-ROR1 antibody (UC961).

Bystander effect study



Her2+ and Her2- cells expressing red and green fluorescence, respectively, were co-cultured with ADC for 7 days, and fluorescence imaging was performed using a live-cell imaging system. Green fluorescence and bar graphs demonstrated specific killing of Her2- cells.

CAR-T Lead Characterization: A Versatile Platform for Functional Evaluations of CAR Leads


From vector construction & T cell transduction to functional evaluation

CAR Expression


Cytotoxicity Evaluation

Cytokine Release


Non-transduced primary T cells




CAR-transduced primary T cells




Luciferase-based killing assay



Live Cell imaging based killing assay (Incucyte)




IFN-γ production




More Case Studies: 1000+ Delivered Projects


PBMC-based ADCC assay




Macrophage-based ADCP assay



Immune checkpoint assay




Cytokine neutralization assay



In Vivo Pharmacology Service

Comprehensive Services from Discovery to Clinical Development



Key Features

Various Modalities	One-stop Platform	Extensive R&D Experience
<ul style="list-style-type: none"> Monoclonal antibodies Bispecific antibodies Antibody drug conjugates Cell and gene therapy Recombinant Proteins Vaccines 	<ul style="list-style-type: none"> In vivo efficacy & DMPK studies Safety evaluation Diverse bioanalytical detection CMC+ Ecology, GMP+GLP Customized services 	<ul style="list-style-type: none"> 30+ drug discovery projects 8+ CGT discovery projects 10+ integrated projects 5+ global IND approvals NMPA/FDA/EMA compliance

In Vivo Pharmacology Platforms

In Vivo Efficacy and Biological Activity Study	Antitumor mouse models <ul style="list-style-type: none"> Syngeneic model Transgenic model CDX model PBMC immune humanization model Metastasis or orthotopic model 	Non-tumor disease models <ul style="list-style-type: none"> Metabolic disease models Autoimmune disease models In vivo bioactivity assay Assisted reproductive drug efficacy Regenerative treatment Customized services
	In vivo DMPK <ul style="list-style-type: none"> Plasma stability Method development and validation PK or PK-PD test ADA & Nabs test Tissue distribution Receptor occupancy 	Bioanalysis <ul style="list-style-type: none"> Tumor Infiltrating Lymphocytes Pathological Tissue Cross-Reactivity Immuno-phenotyping Cytokine testing Tissue chip Customized services
In Vivo Toxicity	Early toxicity (Non-GLP) <ul style="list-style-type: none"> Drug tolerance Animal survival rate Predict toxic effects Other customized services 	GLP toxicity <ul style="list-style-type: none"> Acute toxicity Long-term toxicity Safety pharmacology Tissue cross reactivity Preparation safety Immunotoxicity Genotoxicity Reproductive toxicity



Case Study

Various Ready-to-use Tumor Models for Efficacy Study


200+ tumor cell lines, 80+ tumor cell models, covering 24 tumor indications

24 tumor indications	
Bladder cancer	Lymphoma
Brain cancer	Liver cancer
Breast cancer	Lung cancer
Cervical cancer	Myeloma
Colon cancer	Melanoma
Esophageal cancer	Oral cancer
Endometrial	Ovary cancer
Fibrosarcoma	Pancreas cancer
Gastric cancer	Prostate cancer
Kidney cancer	Rectum cancer
Leukemia	Skin cancer


Efficacy of CD3 bispecific antibody in CDX model with huPBMC transplant




Efficacy of CPis in CDX model with huPBMC transplant




Efficacy of ADC in CDX model




Efficacy of CART in CDX model




IVIS of mice




Comprehensive Biological Analysis Empowers Drug Discovery ProBio's typical workflow




PK service for ADC modalities



Immune typing by FACS



ICRS panel



IHC panel



05

Preliminary Developability Assessment

Preliminary Developability Assessment Service

A Critical Step for Both Antibody Discovery and CMC Development

Developability assessment is one of the most important evaluations in the development of biologics at both the drug discovery and CMC stage. The developability assessment services offered at ProBio may help identify the potential developability risk of Ab lead candidates and select the CMC candidates at discovery stage, and provide critical information to guide the process development & optimization at CMC stage.

Typical Instruments



HPLC/UHPLC System



LC-MS System



DLS System



DSF System



Imaged Capillary Electrophoresis System



Biacore 8K


Service Package (for mAb)

Service	Service content					Deliverables	Timeline	
Basic	Quality attributes	Test item	Stressed conditions				Report: • Tagg • Conc. • Purity	6-8 weeks
			None	40°C	Low pH 3.5			
	Tagg	DLS	✓	-	-			
	Conc.	UV280	✓	✓	✓			
	Purity	SEC-HPLC	✓	✓	✓			
Purity	CE-SDS-NR	✓	✓	✓				
Premium	Quality attributes	Test item	Stressed conditions				Report: • Tagg • Tm • Conc. • Purity • Charge variant profiles	6-8 weeks
			None	40°C	Low pH 3.5	Freeze-thaw		
	Tagg	DLS	✓	-	-	-		
	Tm	DSC	✓	-	-	-		
	Conc.	UV280	✓	✓	✓	✓		
	Purity	SEC-HPLC	✓	✓	✓	✓		
	Purity	CE-SDS-NR	✓	✓	✓	✓		
Charge variants	icIEF	✓	✓	✓	✓			

Want to Get More Informative Data on Developability?

Try our **ProGram** platform to generate high quality material for developability assessment!

- Product quality close to **CMC sample**
- High productivity stable pool: **2-3g/L**
- High batch to batch **consistency** compared to transient
- **12 weeks** from gene synthesis to purified material



ProBio

Our Values

Customer Centric · Innovation · Integrity

Contact us

 www.probiocdmo.com/

 +1-732-885-9188 (US)

 ProBio Inc. Building 9, 311 Pennington Rocky Hill Rd, Pennington, NJ

 USA: cdmo.us@probiocdmo.com

Europe: cdmo.eu@probiocdmo.com

China: cdmo.cn@probiocdmo.com

Japan: cdmo.jp@probiocdmo.com

APAC: cdmo.apac@probiocdmo.com

South Korea: cdmo.kr@probiocdmo.com

